Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 1.04% and Operating profit at -4.26% over the last 5 years
2
With a growth in Net Sales of 28.98%, the company declared Very Positive results in Sep 25
3
With ROE of 5.06%, it has a expensive valuation with a 2.56 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,448 Million (Small Cap)
51.00
NA
2.73%
-0.45
5.35%
0.79
Revenue and Profits:
Net Sales:
104 Million
(Quarterly Results - Sep 2025)
Net Profit:
35 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
42.33%
0%
42.33%
6 Months
6.25%
0%
6.25%
1 Year
22.57%
0%
22.57%
2 Years
10.82%
0%
10.82%
3 Years
6.17%
0%
6.17%
4 Years
-30.43%
0%
-30.43%
5 Years
0%
0%
0.0%
Beijing Scitop Bio-Tech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.04%
EBIT Growth (5y)
-4.26%
EBIT to Interest (avg)
86.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.18
Tax Ratio
14.14%
Dividend Payout Ratio
41.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.24%
ROE (avg)
7.69%
Valuation key factors
Factor
Value
P/E Ratio
51
Industry P/E
Price to Book Value
2.56
EV to EBIT
50.71
EV to EBITDA
35.07
EV to Capital Employed
4.05
EV to Sales
11.49
PEG Ratio
NA
Dividend Yield
0.86%
ROCE (Latest)
7.98%
ROE (Latest)
5.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
104.00
80.70
28.87%
Operating Profit (PBDIT) excl Other Income
30.40
25.80
17.83%
Interest
0.00
0.00
Exceptional Items
0.50
0.20
150.00%
Consolidate Net Profit
35.00
27.70
26.35%
Operating Profit Margin (Excl OI)
292.50%
224.50%
6.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 28.87% vs 4.81% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 26.35% vs -12.62% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
300.40
297.30
1.04%
Operating Profit (PBDIT) excl Other Income
97.40
85.10
14.45%
Interest
0.30
0.50
-40.00%
Exceptional Items
2.00
1.30
53.85%
Consolidate Net Profit
94.40
93.50
0.96%
Operating Profit Margin (Excl OI)
234.80%
216.90%
1.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.04% vs -19.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.96% vs -14.92% in Dec 2023
About Beijing Scitop Bio-Tech Co., Ltd. 
Beijing Scitop Bio-Tech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






